Bispecific monoclonal antibody

Adimab Provides Year-End Update on 2022 Partnership Activities

Retrieved on: 
Tuesday, January 10, 2023
Stem Cells, Biotechnology, Pharmaceutical, General Health, Health, Infectious Diseases, Health Technology, Genetics, G protein-coupled receptor, Control, Ion, Complex, Monoclonal antibody, Cytokine, Bispecific monoclonal antibody, Alnylam Pharmaceuticals, Regeneron Pharmaceuticals, HC, TCR, Biogen, Partnership, Protein, International Association of Students in Agricultural and Related Sciences, Engineering, Stanford University, FC, Antibody, CD3, Immunoglobulin G, Top of the Form (quiz show), Bristol Myers Squibb, DEM, Pharmaceutical industry, Fine chemical, Vaccine, Vertex

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it entered into partnership agreements with 11 new companies in 2022.

Key Points: 
  • Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it entered into partnership agreements with 11 new companies in 2022.
  • In addition, Adimab expanded its collaborations with Biogen, Biotheus, Bristol Myers Squibb, Invivyd, Link Immunotherapeutics, Regeneron, Surface Oncology, and Werewolf.
  • In 2022, Adimab and its partners initiated discovery on 57 new therapeutic programs, bringing the total number of royalty-bearing programs commenced to over 475.
  • “Our growth in the number of therapeutic programs continues to be remarkable,” said Guy Van Meter, Chief Business Officer of Adimab.

Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, IND, Degenerative disease, Autoimmune disease, Janssen, Hoffmann-La Roche, Ipilimumab, Lymphoma, Ovarian cancer, Monoclonal antibody, Janssen Biotech, Bispecific monoclonal antibody, CD28, Cytokine, ICOS, Tumor microenvironment, Psoriasis, ENPP3, RCC, Biology, CLDN6, NK, Immune system, Protein engineering, Ligand, Patient, Genentech, CD3, Atopic dermatitis, Research, Cancer, Claudin, CLDN9, Antibody, Lenalidomide, MCRPC, Vaccine, Pharmaceutical industry, Medicine, Medical imaging, Regulatory T cell

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.
  • “We are building on this momentum in 2023, progressing our clinical portfolio internally and with our co-development partners, including four bispecific antibody programs targeting solid tumors.
  • Xencor plans to:
    Continue enrolling patients into the Phase 1b, multiple-ascending dose study in patients with atopic dermatitis and psoriasis.
  • Xencor ended the fourth quarter of 2022 with unaudited cash, cash equivalents, receivables and marketable debt securities totaling approximately $610 million.

Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform

Retrieved on: 
Thursday, December 22, 2022
MEM, OTCQB, Bi-specific T-cell engager, Research, COVID-19, Biomarker, Virus, USD, CAR, CRS, Patient, Michigan State University, Degenerative disease, Syndrome, Innovation, Cytokine, Cannabinoid, Therapy, Cytokine release syndrome, Immune system, GBLX, Bispecific monoclonal antibody, Vaccine, Pharmaceutical industry

Gb Sciences announced in May 2022 that FHI Clinical would consult and write the draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations.

Key Points: 
  • Gb Sciences announced in May 2022 that FHI Clinical would consult and write the draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations.
  • "Our research shows promise for the potential use of cannabinoids within cannabinoid-containing mixtures as a treatment option for hyperinflammation.
  • Gb Sciences recently published a white paper on their novel development program titled "Utilizing Proprietary AI/ML Technology, Novel Cannabis-Inspired Mixtures Are Developed as Innovative Anti-Inflammatory Therapeutics"; download it here .
  • A proof-of-concept study completed by researchers at Michigan State University in 2021 found that Gb Sciences' proprietary cannabis-inspired minimum essential mixtures (MEM) reduced cytokine release syndrome biomarkers.

Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb’s Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable

Retrieved on: 
Thursday, December 1, 2022
IMCD, COVID-19, Epitope, Ferroptosis, Heart, Charles, Bispecific monoclonal antibody, PD-1, Engineering, Antibody, IND, Safety, Acquisition, Partnership, Biotechnology, Therapy, Ion, Neoplasm, Toxicity, Tumor microenvironment, Protein, Half-life, KDA, Security (finance), Biology, Monoclonal antibody, CDR, H3, Cell death, Mining, Risk, Failure, PD-L1, Coronavirus, Organic acid, Iron, Animal, Complementarity, FDA, Algorithm, Palladium, Fine chemical, Vaccine, Pharmaceutical industry, Minotaur, Hillstream loach

BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”) today announced the development of proprietary targeted biologics, Knob Quatrabodies™ (HSB-1940) against PD-1. Hillstream signed separate collaboration agreements with a subsidiary of OmniAb, Inc. (Nasdaq: OABI) (“OmniAb”) and with Minotaur Therapeutics, Inc. (“Minotaur”) to advance Picobodies against novel, unreachable and undruggable epitopes in high-value validated targets starting with PD-1.

Key Points: 
  • Targeting PD-1 is a step toward enabling Hillstream to enter the rapidly growing Immuno-oncology (IO) therapeutics market with additional IO targets after PD-L1.
  • Alternative species, particularly camelids and bovines, provide a paradigm for antigen recognition through novel domains which form the antigen binding site.
  • However, for camelids, heavy chain antibodies bind antigen with only a single heavy chain variable region, in the absence of light chains.
  • At ~4-6 kDa, these are three times smaller than a camelid nanobody, and are the smallest known antibody fragment.

Compugen to Participate in the JMP Securities Hematology and Oncology Summit

Retrieved on: 
Tuesday, November 29, 2022
AstraZeneca, TEL, Bispecific monoclonal antibody, Hematology, Compugen, Research, Immunotherapy, TIGIT, Pharmaceutical industry, Bayer

HOLON, Israel, Nov. 29, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Anat Cohen-Dayag, Ph.D., President and CEO, and additional members of its management team will participate in a virtual fireside chat at the upcoming JMP Securities Hematology and Oncology Summit.

Key Points: 
  • HOLON, Israel, Nov. 29, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Anat Cohen-Dayag, Ph.D., President and CEO, and additional members of its management team will participate in a virtual fireside chat at the upcoming JMP Securities Hematology and Oncology Summit.
  • The fireside chat will take place on Tuesday, December 6, 2022, at 10:20 am ET.
  • A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com .
  • Compugenis headquartered in Israel, with offices in South San Francisco, CA.Compugen'sshares are listed on Nasdaq and the Tel AvivStock Exchange under the ticker symbol CGEN.

AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022

Retrieved on: 
Monday, November 28, 2022
Internet, AMG, Genetics, Bispecific monoclonal antibody, AMGN, Biotechnology, GIPR, Patient, Dow Jones Industrial Average, Disease, Webcast, Insulin resistance, Therapy, Barron's, Calendar, Biology, Fine chemical, Broadcasting, Amgen, Research

THOUSAND OAKS, Calif., Nov. 28, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m.

Key Points: 
  • THOUSAND OAKS, Calif., Nov. 28, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m.
  • The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
  • Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.
  • In 2022, Amgen was named one of the "World's Best Employers" by Forbes and one of "America's 100 Most Sustainable Companies" by Barron's.

Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting

Retrieved on: 
Monday, November 21, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Bispecific monoclonal antibody, Neoplasm, Investment, PK, Annual general meeting, TAAS, Fab, PD-L1, Eli Lilly and Company, Ligation, TME, LAG3, CDH, TAM, Cancer, Macrophage, Myelocyte, B cell, CD47, Tumor microenvironment, ADCP, LILRB2, Coronavirus Scientific Advisory Board (Turkey), Family, Mab, SITC, SIGLEC, Patient, Antibody, Fine chemical, Vaccine

Elpiscience Biopharmaceuticals, Inc. (Elpiscience), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRP monoclonal antibody ES004, PD-L1/SIRP bispecific antibody ES019, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and anti-LAG3 monoclonal antibody ES005.

Key Points: 
  • Elpiscience Biopharmaceuticals, Inc. (Elpiscience), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRP monoclonal antibody ES004, PD-L1/SIRP bispecific antibody ES019, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and anti-LAG3 monoclonal antibody ES005.
  • Anti-SIRP mAb ES004 potently potentiates antibody dependent cellular phagocytosis (ADCP) activity of antibodies against tumor associated antigens (TAAs) in vitro and in vivo.
  • Elpiscience has identified a novel function of SIGLEC15 that SIGLEC15 can induce monocyte apoptosis and its inhibitory effect on T cell function is indirect.
  • To learn more about the studies, please visit Elpiscience official website https://www.elpiscience.com
    Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapy to benefit cancer patients worldwide.

Compugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1/TIGIT Bispecific

Retrieved on: 
Wednesday, November 16, 2022
Securities Act of 1933, SEC, U.S. Securities and Exchange Commission, Security (finance), Bispecific monoclonal antibody, Immunotherapy, Therapy, Compugen, Forward-looking statement, PVRIG, Risk, TIGIT, AstraZeneca, Company, Nasdaq, Terminology, Compugen (Israeli company), Research, Securities Exchange Act of 1934, Annual report, FC, Private Securities Litigation Reform Act, PVRL2, COVID-19, NASDAQ, TEL, Antibody, ClinicalTrials.gov, Fine chemical, Pharmaceutical industry, Bayer

"Like COM902, AZD2936 was engineered to reduce Fc effector functionality, with the potential to enhance anti-tumor activity.

Key Points: 
  • "Like COM902, AZD2936 was engineered to reduce Fc effector functionality, with the potential to enhance anti-tumor activity.
  • We believe that this is the optimal design and look forward to seeing how it plays out in the clinic."
  • Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen.
  • Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting

Retrieved on: 
Friday, November 11, 2022
Securities and Exchange Commission (Philippines), Melanoma, United Kingdom, Company, Survival, Annual report, Risk, Private Securities Litigation Reform Act, TCR, Security (finance), Cancer, Bispecific monoclonal antibody, Melanocyte, Adult, Autoimmunity, Pascal (microarchitecture), Patient, Safety, Anti-CD3 monoclonal antibody, COVID-19, Infection, HIV disease progression rates, Autoimmune disease, Vaccine, Pharmaceutical industry, Immunocore, Mum

KIMMTRAK is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function.

Key Points: 
  • KIMMTRAK is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function.
  • KIMMTRAK specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma.
  • KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
  • This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America

Retrieved on: 
Wednesday, November 9, 2022
Growth, Cytokine release syndrome, Infection, Melanoma, Chills, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PIM, Rash, Bispecific monoclonal antibody, Vomiting, Nasdaq, Autoimmune disease, Immunocore, Risk, Hypotension, EMA, Uveal melanoma, European Medicines Agency, Vital signs, Partnership, Fatigue, CRS, Creatinine, Fetus, Eye, ALT, FDA, ImmTAC, Anti-CD3 monoclonal antibody, Headache, Melanocyte, LATAM, AST, Edema, Breakthrough therapy, CEO, Food, Birth, Nausea, Patient, Abdominal pain, TGA, Health Canada, Cancer, Lymphocyte, Pascal (microarchitecture), TCR, Hypoxia, Xeroderma, Itch, Glucose, Pharmaceutical industry, Medical device, Medical imaging, Fever, Medison

PETACH TIKVAH, Israel, Nov. 9, 2022 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, today announced the addition of South and Central America and the Caribbean markets ("Latin America") to its multi-territorial agreement with Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease.

Key Points: 
  • "The expansion of our partnership with Immunocore into LATAM is a significant milestone in building our unified commercial platform in all international markets," says Meir Jakobsohn, Founder and CEO of Medison.
  • In this case, offering patients in Latin America hope in the form of a treatment for this rare and aggressive form of melanoma that affects the eye."
  • With this latest growth, Medison increases its commercial presence across Israel, Central and Eastern Europe, Canada, Asia-Pacific, South and Central America and the Caribbean countries.
  • Medison has a track record of multi-territorial partnerships with leading pharmaceutical and biotech companies seeking to expand their global reach.